In this issue of Cancer Cell, Zhao and colleagues test various chimeric antigen receptor (CAR) T cells to show that CD28-CD3ζ CAR T cells that constitutively express 4-1BBL promote T cell expansion and tumor eradication while reducing exhaustion. The results have important implications for the development of effective CAR T cell therapies in cancer patients
In the past decade, chimeric antigen receptor (CAR) T cell technology has revolutionized cancer immu...
BACKGROUND: Co-stimulatory signals regulate the expansion, persistence, and function of chimeric ant...
CD19-targeting CAR T cells have shown potency in clinical trials targeting B cell leukemia. Although...
In this issue of Cancer Cell, Zhao and colleagues test various chimeric antigen receptor (CAR) T cel...
In this issue of Cancer Cell, Zhao and colleagues test various chimeric antigen receptor (CAR) T cel...
Chimeric antigen receptor (CAR)-T cells showed great activity in hematologic malignancies. However, ...
Second-generation (2G) chimeric antigen receptors (CARs) targeting CD19 are highly active against B ...
Despite the benefits of chimeric antigen receptor (CAR)–T cell therapies against lymphoid malignanci...
Background: T cells expressing chimeric antigen receptors (CARs) have shown exciting promise in canc...
T cells genetically modified to express a CD19-specific chimeric antigen receptor (CAR) for the inve...
BackgroundT cells expressing chimeric antigen receptors (CARs) have shown exciting promise in cancer...
CAR-T cell therapy has emerged as a promising cancer treatment modality with curative potential. In ...
With breakthroughs in synthetic biology, improved cell culture techniques and advanced genetic engin...
Chimeric antigen receptor (CAR) T-cell therapy has been shown to be dramatically effective in the tr...
Chimeric Antigen Receptor (CAR) T cell therapies for hematologic malignancies have been astonishingl...
In the past decade, chimeric antigen receptor (CAR) T cell technology has revolutionized cancer immu...
BACKGROUND: Co-stimulatory signals regulate the expansion, persistence, and function of chimeric ant...
CD19-targeting CAR T cells have shown potency in clinical trials targeting B cell leukemia. Although...
In this issue of Cancer Cell, Zhao and colleagues test various chimeric antigen receptor (CAR) T cel...
In this issue of Cancer Cell, Zhao and colleagues test various chimeric antigen receptor (CAR) T cel...
Chimeric antigen receptor (CAR)-T cells showed great activity in hematologic malignancies. However, ...
Second-generation (2G) chimeric antigen receptors (CARs) targeting CD19 are highly active against B ...
Despite the benefits of chimeric antigen receptor (CAR)–T cell therapies against lymphoid malignanci...
Background: T cells expressing chimeric antigen receptors (CARs) have shown exciting promise in canc...
T cells genetically modified to express a CD19-specific chimeric antigen receptor (CAR) for the inve...
BackgroundT cells expressing chimeric antigen receptors (CARs) have shown exciting promise in cancer...
CAR-T cell therapy has emerged as a promising cancer treatment modality with curative potential. In ...
With breakthroughs in synthetic biology, improved cell culture techniques and advanced genetic engin...
Chimeric antigen receptor (CAR) T-cell therapy has been shown to be dramatically effective in the tr...
Chimeric Antigen Receptor (CAR) T cell therapies for hematologic malignancies have been astonishingl...
In the past decade, chimeric antigen receptor (CAR) T cell technology has revolutionized cancer immu...
BACKGROUND: Co-stimulatory signals regulate the expansion, persistence, and function of chimeric ant...
CD19-targeting CAR T cells have shown potency in clinical trials targeting B cell leukemia. Although...